Seville Oranges

5 interactions on record

Seville Oranges has 5 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Nirogacestat, Ibrutinib, Lonafarnib. Patients taking Seville Oranges should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 5
Major: 1
Moderate: 4

Major (1)

Seville Oranges + Nirogacestat— Strong CYP3A inhibitor. Increases nirogacestat exposure, which may increase risk of adverse reactions.

Moderate (4)

Seville Oranges + Ibrutinib— Contains strong or moderate CYP3A inhibitors. Should be avoided during ibrutinib treatment to prevent increased ibrutini…
Seville Oranges + Lonafarnib— Avoid consumption of grapefruit or Seville oranges during lonafarnib therapy due to CYP3A inhibition.
Seville Oranges + Lurbinectedin— Seville oranges contain strong or moderate CYP3A inhibitors that increase lurbinectedin systemic exposure, which may inc…
Seville Oranges + Rilzabrutinib— Seville oranges are strong CYP3A inhibitors. Concomitant use increases rilzabrutinib exposure and risk of adverse reacti…

Seville Oranges + Nirogacestat⚠️Major

Strong CYP3A inhibitor. Increases nirogacestat exposure, which may increase risk of adverse reactions.

Seville Oranges + Ibrutinib🟡Moderate

Contains strong or moderate CYP3A inhibitors. Should be avoided during ibrutinib treatment to prevent increased ibrutinib concentrations.

Seville Oranges + Lonafarnib🟡Moderate

Avoid consumption of grapefruit or Seville oranges during lonafarnib therapy due to CYP3A inhibition.

Seville Oranges + Lurbinectedin🟡Moderate

Seville oranges contain strong or moderate CYP3A inhibitors that increase lurbinectedin systemic exposure, which may increase incidence and severity of adverse reactions.

Seville Oranges + Rilzabrutinib🟡Moderate

Seville oranges are strong CYP3A inhibitors. Concomitant use increases rilzabrutinib exposure and risk of adverse reactions.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.